But the positive report, which matched Wall Street expectations, comes on the heels of a warning letter from the Food and Drug Administration that reprimands the company for failing to correcta longstanding defect in one of its drug infusion pumps.
"With enzyme replacement, it's a single defect, and you correct that error, " says Joon Yun , partner at money management firm Palo Alto Investors, which has owned BioMarin stock for several years.